Replies to post #135838 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

We are now at an inflection point where the understanding, sophistication, detail and cost of analysis is beginning to make precision medicine the better financial choice over hope and pray type of trials with post hoc analysis paralysis trying to rescue some revenue from the remains of failed hypothesis and financial black holes.

IMO, you are exactly right. IMO, this process inflection is analogous to when Microprocessors began to replace discrete components in electronic systems. Technology lead by leaps and bounds as cost/function lead, only constrained by knowledge. That took about 10 years to catch on.

We are seeing the transition of medicine/research to an application of hard/soft science w/less to almost no emphasis on the historical art form.
In this context AVXL is a new Apple, IMO.